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Edited by Veli-Pekka LehtoAbstract Peroxisome proliferator-activated receptor c
(PPARc) is a nuclear receptor modulating a variety of biological
functions including cancer cell proliferation and diﬀerentiation.
However, the role of PPARc and its ligands in tumor invasion
is unclear. To evaluate a possible role for PPARc ligands in tumor
invasion, we examined whether PPARc agonists including pioglit-
azone, troglitazone, rosiglitazone, and ciglitazone could aﬀect the
activity of matrix metalloproteinases (MMPs) in the HT1080 cell
line, a well-studied and well-characterized cell line for MMP re-
search. The gelatin zymography assay showed that ciglitazone
activated pro-MMP-2 signiﬁcantly. In addition, ciglitazone in-
creased the expression of MMP-2, which was accompanied by
an increase of membrane type 1-MMP (MT1-MMP) expression.
The PPARc antagonist, GW9662 attenuated the ciglitazone-in-
duced PPARc activation but it did not aﬀect the pro-MMP2 acti-
vation by ciglitazone, suggesting that the action of ciglitazone on
the pro-MMP-2 activation bypassed the PPARc pathway. Anti-
oxidants and various inhibitors of signal transduction were used to
investigate the mechanism of ciglitazone-induced pro-MMP-2
activation. We found that the sustained production of reactive
oxygen species (ROS) was required for pro-MMP-2 activation
by ciglitazone. We also found that PB98059, an inhibitor of
MEK-ERK, signiﬁcantly blocked ciglitazone-induced pro-
MMP-2 activation and that extracellular signal-regulated kinase
(ERK) was hyperphosphorylated by ciglitazone. Moreover, cell
invasion was signiﬁcantly increased by ciglitazone in the
HT1080 cell lines, whereas cell motility was not aﬀected. This
study suggests that ciglitazone-induced pro-MMP-2 activation
increases PPARc-independent tumor cell invasion through ROS
production and ERK activation in some types of cancer cells.
 2007 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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The metastatic cascade consists of several sequential steps,
including cells migration from the primary tumor, invasion
of the local tissue, entry of the circulation, residence in a dis-
tant vascular bed, extravasation into the target organ, and pro-
liferation as a secondary colony. Among these steps, tumor
invasion is important [1]. The matrix metalloproteinases
(MMPs) are the key family of proteolytic enzymes involved
in the tumor invasion [2]. These enzymes are classiﬁed into col-
lagenases, gelatinases, stromelysins, and membrane-type
MMPs and can collectively degrade all components of the
extracellular matrix [3]. Tissue inhibitors of metalloproteinases
(TIMPs) complex with MMPs and regulate the activity of indi-
vidual MMPs [4,5]. MMPs and TIMPs play a signiﬁcant role
in facilitating tumor invasion and metastasis not only by
degrading the extracellular matrix but also by interacting with
other biological molecules such as cell adhesion molecules,
cytoskeletal proteins, and growth factors [6,7]. MMP-2 (gela-
tinase A, type IV collagenase) and MMP-9 (gelatinase B, type
IV collagenase) are important for degrading type IV collagen
which is a major component of the basement membrane.
MMP-2 and MMP-9 are abundantly expressed in various
malignant tumors and have been implicated in tumor invasion
and metastasis [8,9]. MMP-2 is secreted as an inactive zymogen
that can be activated by the action of highly expressed MT1-
MMP [10].
Peroxisome proliferator-activated receptor c (PPARc), a
member of the nuclear hormone receptor superfamily, is a li-
gand-dependent transcription factor that regulates gene expres-
sion by binding as a heterodimer with a retinoid X receptor
(RXR) to speciﬁc peroxisome proliferator response elements
(PPREs) in enhancer sites [11,12]. It is activated not only by
its natural agonists such as 15-deoxy-D12,14 prostaglandin J2
and fatty-acid derivatives but also by the synthetic agonists of
thiazolidinediones (TZDs) including ciglitazone (CIG), pioglit-
azone (PGZ), rosiglitazone (RSG), and troglitazone (TGZ)
[13]. Studies using PPARc ligands have implicated PPARc in
cell-growth inhibition in a wide variety of tumor cells [14–17].
This has raised considerable interest in the possible use of
PPARc ligands as tumor-preventative and tumor-therapeutic
agents. Most studies have focused on the anti-growth eﬀect of
PPARc ligands on tumor cells. Very little is known about
the role of PPARc ligands in cancer cell invasion. Here, we
show that pro-MMP-2 is activated by the PPARc agonistation of European Biochemical Societies.
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cells. Interestingly, this does not involve PPARc activation
but rather the production of reactive oxygen species (ROS) fol-
lowed by the activation of extracellular signal-regulated kinase
(ERK).2. Materials and methods
2.1. Cell culture and materials
HT1080 ﬁbrosarcoma cells were grown in DMEM supplemented
with 50 mg/l gentamicin (Invitrogen) and 10% fetal bovine serum in
an atmosphere of 95% air and 5% CO2. Experimental cultures were
grown in serum-starved medium for 4 h and stimulated with the appro-
priate chemicals as indicated. Ciglitazone, rosiglitazone, troglitazone,
pioglitazone and GW9662 were purchased from Cayman chemical
(Ann Arbor, MI). AG1024, AG1295, AG1478, SU1498, genistein,
indometacin, LY294002 and PD98059 were purchased from Calbio-
chem (La Jolla, CA). 2 0,7 0-Dichloroﬂuorescin diacetate (DCFH-DA)
were purchased from Sigma (St Louis, MO). Antibodies against
PPARc and phospho-ERK were purchased from Cell Signaling Tech-
nology (Hitchin, Hertfordshire). Antibody against MMP-2 was from
Chemicon International (Temecula, CA). Anti-MT1-MMP, anti-
ERK and b-actin antibodies were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA).
2.2. Cell viability
3-[4,5-Dimethylthiazol-2yl]-2,5-diphenyltetrazolium bromide
(MTT) (Roche Molecular Biochemicals) assay was performed. Cells
were plated in 96 wells. After incubation, MTT was added for the ﬁ-
nal concentration to be 0.5 mg/ml. After incubation for 4 h, media
were removed and 0.1 ml of DMSO was added. After dissolving
the formazan, the absorbance was measured at 570 nm with ELISA
reader and the reference absorbance was measured at 655 nm for
the control.
2.3. Zymography
Enzymatic activities of MMP-2 and MMP-9 were assayed by gelatin
zymography. Conditioned media from the cell culture were analyzed
for gelatin degradation activity by SDS–PAGE under non-reducing
conditions. 1 mg/ml gelatin was prepolymerized on a 10% polyacryl-
amide gel as a substrate. Electrophoresis was carried out at 4 C.
The gel was washed twice with washing buﬀer (50 mM Tris–HCl, pH
7.5, 100 mM NaCl, 2.5% Triton X-100), followed by a brief rinsing
in washing buﬀer without Triton X-100. Gelatinolytic activity was
developed in an incubation buﬀer (50 mM Tris–HCl, pH 7.5,
150 mM NaCl, 10 mM CaCl2, 0.02% NaN3, 1 lM ZnCl2) at 37 C
for 16 h and visualized by staining the gel with Coomassie Blue R-
250. A clear zone of gelatin digestion that appeared indicated the pres-
ence of MMPs.
2.4. Western blot analysis
Protein extracts (50 lg) were separated by SDS–PAGE on 10%
polyacrylamide gels and transferred onto nitrocellulose membranes.
The membranes were blocked with 5% skim milk or 3% bovine
serum albumin and probed with an antibody speciﬁc for the proteins
of interest. The membranes were then incubated with a horseradish-
peroxidase-conjugated secondary antibody and developed with
chemiluminescent ECL reagents (Amersham, Piscataway, NJ). To
determine that the amount of protein in each lane was comparable,
the membranes were stripped and probed with antibody against
b-actin.
2.5. RT-PCR
Total RNA from cultured cells was isolated using TRI reagent
(Molecular Research Center) and reverse-transcribed into cDNA using
reverse transcriptase (Promega) and oligo(dT). cDNA aliquots corre-
sponding to 1 lg RNA were semi-quantitatively analyzed by PCR.
The following primers were used for PCR analysis: MT1-MMP, 5 0-
gaa taa cca agt gat gga tgg ata c-3 0 and 5 0-ttt gtt ccc ctt gta gaa gta
agt g-3 0; MMP-2, 5 0-aga tct gca aac agg aca ttg tat t-3 0 and 5 0-ttc ttc
ttc acc tca ttg tat ctc c-3 0; TIMP-2, 5 0-gag aca aag agg aga gaa agtttg c-3 0 and 5 0-ttt atc tgc ttg atc tca tac tgg a-3 0; and GAPDH, 5 0-
cca tgg aga agg ctg ggg-3 0 and 5 0-caa agt tgt cat gga tga cc-30. PCR
products were resolved on 1% agarose gels and visualized by ethidium
bromide staining.2.6. Transfection and luciferase assay
HT1080 cells were plated in 6-well plates. DNA constructs were
transfected using LipofectAMINE 2000 reagent according to the
manufacturer’s instructions (Invitrogen, Carlsbad, CA). 2 lg pGL3-
MT1-MMP reporter vector was co-transfected with 0.5 lg galactosi-
dase [18] and 1 lg PPARc expression vector was co-transfected with
1 lg (PPRE · 3)-tk-luciferase and 0.5 lg b-galactosidase expression
vector. After 24 h of transfection, the luciferase activities were mea-
sured using the luminometer. b-galactosidase activities were measured
using O-nitrophenyl-galactopyranoside as a substrate. (PPRE · 3)-
tk-luciferase and PPARc expression vector were kindly provided by
Dr. Young Yang (Korea Research Institute of Bioscience and Bio-
technology).
2.7. Measurement of ROS formation
Generation of ROS was assessed by using the oxidation sensitive
ﬂuorescent probe 2 0,7 0-dichlorodihydroﬂuorescein diacetate (DCFH-
DA, Sigma). HT1080 cells were pre-treated with 4 lM ciglitazone for
various incubation times. Cells were incubated with 5 lM DCFH-
DA for 30 min at 37 C, harvested and followed by analysis in a con-
focal microscopy (Zeiss) and FACScan ﬂow cytometry (Becton–Dick-
inson). For confocal microscopy analysis, cells were plated onto a Lab-
Tek chamber slide (Nunc) and treated with ciglitazone.2.8. Cell invasion and motility assay
Transwell chamber was used for each invasion assay. The lower and
upper parts of Transwell (Corning Glass) were coated with 10 ll of
type I collagen (0.5 mg/ml) and 20 ll of 1:2 mixture of Matri-
gel:DMEM, respectively. 5 · 104 cells were plated on the upper com-
partment of a Transwell chamber. The medium of the lower
chambers also contained 0.1 mg/ml bovine serum albumin. After incu-
bation for 18 h, cells that had penetrated through the ﬁlters were
counted. The lower surface of the membrane was ﬁxed with methanol
and stained with hematoxylin and eosin. Random ﬁelds were counted
under a light microscope.
To examine the eﬀect of the agents on cell motility, cells were seeded
into Transwell on membrane ﬁlters coated with 10 ll of type I collagen
(0.5 mg/ml) at the bottom of the membrane. Migration in the absence
or presence of agents was measured as described in the invasion assay.
In addition to this, cell motility was measured using a wound-healing
method. Cells were grown to near-conﬂuency, and a wound was cre-
ated with the blunt end of a tip. This was documented through time-
lapse photography.
2.9. Statistical analysis
All data were represented as means ± S.D. for three or more inde-
pendent experiment. Statistical signiﬁcance was evaluated using t-test
for unpaired data using SPSS software (Norusis SPSS Inc, Release
6.0).3. Results
3.1. Pro-MMP-2 activation by ciglitazone in HT1080 cells
We examined the eﬀect of PPARc agonists on MMP activa-
tion in HT1080 cells (Fig. 1). After treatment with each of the
PPARc agonists, pioglitazone, troglitazone, rosiglitazone, and
ciglitazone, cell viability was tested by MMT assays and MMP
activity was assayed by gelatin zymography. As shown in
Fig. 1A, treatment with non-cytotoxic concentrations of ciglit-
azone signiﬁcantly induced pro-MMP-2 activation in a dose-
dependent manner without aﬀecting pro-MMP-9 activity.
Ciglitazone-induced pro-MMP-2 activation was also time-
Fig. 1. Eﬀects of various PPARc agonists on HT1080 cell viability and MMPs activity. (A) Various concentrations of pioglitazone, troglitazone,
rosiglitazone and ciglitazone were treated to the HT1080 cells. After 2 days, the viability was tested by MTT assay. Data represent means ± S.D.
(n = 6). Conditioned media were collected, and gelatin zymography analysis was performed. (B) 4 lM ciglitazone was treated to the HT1080 cells,
and conditioned media were collected as the indicated times. Gelatin zymography was performed to measure the pro-MMP-2 activity. (C) After
treated with PPARc agonists as indicated, conditioned media were collected and concentrated. MMP-2 expression was identiﬁed by Western blot
analysis using an anti-MMP-2 antibody. To demonstrate equal loading, the Ponceau-S stained membrane is shown.
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of pioglitazone, troglitazone and rosiglitazone did not aﬀect
pro-MMP-2 and MMP-9 activities (Fig. 1A). The active form
of pro-MMP-2 shown in the gelatin zymography was speciﬁ-
cally identiﬁed by Western blotting using an anti-MMP-2 anti-
body (Fig. 1C).3.2. Increase of MT1-MMP expression by ciglitazone
Since pro-MMP-2 activation requires the assembly of a mul-
ti-molecular complex involving pro-MMP-2, MT1-MMP and
TIMP-2, we examined the eﬀect of ciglitazone on the expres-
sion of MT1-MMP, MMP-2, and TIMP-2 by semi-quantita-
tive RT-PCR. As shown in Fig. 2A, the expression of MT1-
Fig. 2. Increase of MT1-MMP expression by ciglitazone. (A) HT1080
cells were treated with 4 lM ciglitazone for the indicated times, and
RNA was extracted. Semi-quantitative RT-PCR was carried out. The
expression level was normalized using the signal obtained with
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). (B) After
treated with 2 or 4 lM ciglitazone for 48 h, cell lysates were obtained
and Western blots were performed using an anti-MT1-MMP antibody.
(C) MT1-MMP promoter-containing luciferase vectors were transfec-
ted, and various concentrations of ciglitazone were treated. After 36 h,
luciferase activity was measured. Data represent means ± S.D. (n = 3)
of three experiment. Results were statistically signiﬁcant (*P < 0.01)
using a t-test for unpaired data.
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a time-dependent manner. MT1-MMP protein expression was
also increased by ciglitazone (Fig. 2B). Using promoter/lucifer-
ase constructs, MT1-MMP promoter activity was examined.
As shown in Fig. 2C, ciglitazone increased the activity of the
MT1-MMP promoter 3-fold in a concentration-dependent
manner, demonstrating the transcriptional activation of
MT1-MMP by ciglitazone.
3.3. PPARc-independent pro-MMP2 activation by ciglitazone
Of the various PPARc agonists, only ciglitazone activated
pro-MMP-2, as shown in Fig. 1A. Therefore, we hypothesized
that ciglitazone-induced pro-MMP2 activation was indepen-
dent on the PPARc pathway. To clarify this, we used the
PPARc antagonist, GW9662. We examined whether ciglitaz-one and GW9962 function as a PPARc agonist and PPARc
antagonist, respectively, in HT1080 cells. Western blotting
showed that PPARc was expressed to a considerable degree
in HT1080 cells (data not shown). Transient reporter-gene as-
says showed that ciglitazone increased the PPARc-mediated
luciferase activity in HT1080 cells co-transfected with PPRE-
tk-luciferase and PPARc expression vector (Fig. 3A). The
PPARc antagonist, GW9662, blocked PPARc trans-activation
induced by ciglitazone (Fig. 3B). However, GW9662 did not
block the eﬀect of ciglitazone on pro-MMP-2 activation
(Fig. 3C). Therefore, we concluded that ciglitazone activated
pro-MMP-2 through a PPARc-independent pathway.3.4. Involvement of ROS production and ERK activation in pro-
MMP-2 activation by ciglitazone
Previously, we reported that the sustained production of
ROS activated pro-MMP-2 in HT1080 cells [18]. Therefore,
we examined whether MMP-2 activation could be modulated
by a change in ROS production. Pretreatment with the antiox-
idant, N-acetylcysteine (NAC), inhibited the eﬀect of ciglitaz-
one on pro-MMP-2 activation (Fig. 4A). In addition, the
production of ROS was increased in ciglitazone-treated cells
in a time-dependent manner (Fig. 4B and C). This result sug-
gested that pro-MMP-2 activation by ciglitazone occurred
through the sustained production of ROS.
To understand the mechanism of action of ciglitazone on
MMP-2 activation, we examined the eﬀect of various inhibi-
tors of cell signaling molecules on pro-MMP-2 activity. In par-
ticular, PD98059, an inhibitor of the mitogen activated protein
kinase/extracellular signal-regulated kinase–kinase–extracellu-
lar signal-regulated kinase (MEK-ERK) pathway, signiﬁcantly
inhibited pro-MMP-2 activation by ciglitazone in a dose-
dependent manner. Pro-MMP-2 activation was completely
blocked by 50 lM PD98059 (Fig. 5A). In addition, PD98059
reduced the increase in MT1-MMP trans-activation by ciglit-
azone (Fig. 5B). Hyperphosphorylation of ERK1 and ERK2
was induced by ciglitazone in a time-dependent manner with
no change in ERK1/ERK2 protein expression (Fig. 5C) dem-
onstrating that ERK activation was required for MMP-2 acti-
vation by ciglitazone. AG1024 (an insulin-like growth factor-1
and insulin pathway inhibitor), AG1295 (a platelet-derived
growth-factor pathway inhibitor), AG1478 (an epidermal
growth-factor pathway inhibitor), SU1498 (a VEGF-pathway
inhibitor), indometacin (a phospholipase A2 inhibitor, a cyclo-
oxygenase inhibitor), genistein (a tyrosine kinase inhibitor)
and LY294002 (a phosphatidylinositol 3-kinase inhibitor)
had no eﬀect on pro-MMP-2 activation by ciglitazone (data
not shown).3.5. Increase in cell invasion by ciglitazone
Pro-MMP-2 activation is involved in cell invasion. To exam-
ine whether ciglitazone had the ability to inﬂuence cell invasion
in HT1080 cells, an invasion assay was performed using Trans-
well chambers. The invasive activity was signiﬁcantly increased
by treatment with ciglitazone in a dose-dependent manner
(Fig. 6A). However, ciglitazone did not aﬀect cell motility
using Transwell chambers (Fig. 6B). In addition, cell motility
was estimated using the wound-healing method and ciglitazone
did not aﬀect the extent of the wounded region (data not
shown). From these results, we suggest that ciglitazone in-
creases cell-invasive activity but does not aﬀect cell motility.
Fig. 3. PPARc-independent pro-MMP2 activation by ciglitazone. HT1080 cells were co-transfected with PPARc expression vector and PPRE-tk-
luciferase vector. Various concentrations of ciglitazone alone (A) or its combinations with GW9662 (B) were treated. After 24 h of incubation,
luciferase activity was measured. Data represent means ± S.D. (n = 3) of three experiment. Results were statistically signiﬁcant (*P < 0.01) using a t-
test for unpaired data. (C) Cells were treated with ciglitazone alone or its combination with GW9662, their conditioned media were collected, and
gelatin zymography was performed.
Fig. 4. Involvement of ROS production in pro-MMP2 activation by
ciglitazone. (A) HT1080 cells were pre-treated with NAC for 2 h and
incubated with 3 lM ciglitazone for 48 h. Conditioned media were
collected and zymography analysis was performed. To measure the
production of ROS, HT1080 cells were treated with 4 lM ciglitazone
for 0 h, 24 h and 48 h. Cells were incubated with 5 lM DCFH-DAs
and analyzed by ﬂow cytometry (B) and confocal microscopy (C).
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Many reports have shown that PPARc agonists induce ter-
minal diﬀerentiation, cell-cycle arrest, and apoptosis in several
types of cancer cells [14–17]. However, there has been a contro-
versy concerning the potential therapeutic value of PPARc
agonists for treating cancers. PPARc activation by PPARc
agonists enhances the development of colonic tumors in mice
that have a mutation in the adenomatosis polyposis coli
(APC) tumor suppressor gene [19,20]. Mutational analysis of
PPARc has led to the report that the mutation of the PPARc
gene is a very rare event in human malignancies [21]. In partic-
ular, no signiﬁcant eﬀects on tumor development have been
found with any type of PPARc deletion. PPARc-deleted
mouse, that were generated using the Cre-loxP recombination
system, had no increase in the incidence of mammary tumors
[22]. Hemizygous deletion of PPARc in a mouse model of
prostate cancer did not alter the development of cancer [23].
It also has been reported that PPARc signaling can act as a tu-
mor promoter in a mammary gland tumor [24]. These results
suggest that PPARc is not a dominant tumor suppressor. At
present, the role of PPARc in cancer remains a subject of de-
bate.
Metastasis is the main cause of death in cancer patients.
Although MMPs play a crucial role in tumor metastasis, it is
unclear how PPARc aﬀects MMP activity. Although some
groups have reported that PPARc agonists inhibit the inva-
siveness of breast cancer and pancreatic cancer cells [25,26],
this does not mean that the anti-invasive eﬀects of PPARc ago-
nists are universal in all types of cancer. Here, we have exam-
ined the eﬀect of PPARc agonists on tumor cell invasion and
MMP activity in HT1080 cells. Our results show that among
various PPARc agonists, pro-MMP-2 activation is speciﬁcally
Fig. 5. Involvement of ERK activation in pro-MMP2 activation by
ciglitazone. (A) After pre-treatment with various concentrations of
PD98059 for 2 h, cells were incubated with 3 lM ciglitazone for 2 days
and followed by zymography analysis. (B) HT1080 cells transfected
with MT1-MMP promoter-containing luciferase vectors were pre-
treated with 50 lM PD98059 for 2 h and incubated with 3 lM
ciglitazone. After 36 h, luciferase activity was measured. Data repre-
sent means ± S.D. (n = 3) of three experiment. Results were statisti-
cally signiﬁcant (*P < 0.01) using a t-test for unpaired data. (C)
HT1080 cells were treated with 4 lM ciglitazone and harvested at the
indicated time and Western blot analysis was performed using an anti-
phospho-ERK and an anti-ERK antibodies.
Fig. 6. Eﬀect of ciglitazone on the motility and the invasion of
HT1080 cells. (A) HT1080 cells were seeded into Transwell coated with
collagen and matrigel and incubated with ciglitazone for 18 h. Cell
invasion assay was performed as described in Section 2. (B) Cells were
seeded into Transwell coated with collagen and incubated with
ciglitazone and the motility assay was performed as described in
Section 2. Data represent means ± S.D. (n = 3) of three experiment.
*P < 0.05, **P < 0.01 compared with control (CIG 0 lM) using a t-test
for unpaired data.
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PPARc antagonist GW9662 in HT1080 cells (Fig. 3). This re-
sult leads to the conclusion that pro-MMP-2 activation by cig-
litazone is not related to PPARc activation. Many reports
have shown that PPARc ligands act independently of PPARc
in various biological functions, including the inhibition of
mitochondrial fuel oxidation, inhibitory eﬀects on cytokine
production and inﬂammation, MAP kinase activation, and
even anti-tumorigenic events [27–29]. Our results can be added
to the list of PPARc-independent actions of PPARc ligands.
It is well known that ROS is involved in tumor metastasis.
We have previously reported that the sustained production
of ROS by phenazine methosulfate (PMS) induces pro-
MMP-2 activation through the induction of MT1-MMP in
HT1080 cells [18]. In addition, it has been reported that the
overexpression of manganese superoxide dismutase or treat-
ment with xanthine/xanthine oxidase induces pro-MMP2 acti-
vation and that mechanical stretch enhances the expression of
MMP-2 via ROS [30,31]. Here, we show that ciglitazone in-
duces the production of ROS in the HT1080 cell line
(Fig. 4). Among PPARc agonists, ROS generation may be spe-
ciﬁc to ciglitazone. Rosiglitazone and troglitazone produced
far smaller amounts of ROS and pioglitazone did not produceROS in HT1080 cells (data not shown). Similarly, studies on
the primary cultures of astrocytes and glioma cells showed that
ciglitazone produced more ROS than rosiglitazone [32]. There-
fore, we suggest that in some cases ciglitazone may act inde-
pendently of PPARc via the production of large amounts of
ROS.
Our report shows that PPARc ligands activate MAP kinase
signaling through a PPRE-independent mechanism. The
PPRE-dependent and -independent pathways most likely
interrelate, since the activation of the MAP kinase pathway
by PPARc ligands ultimately leads to the regulation of the
PPRE-dependent pathway through inhibitory phosphoryla-
tion of PPARc [33]. It is possible that the balance between
the two pathways may account for the observed ability of
PPAR ligands to act as both pro- and anti-proliferative drugs.
Therefore, we have further examined the downstream signaling
pathway of ciglitazone-induced pro-MMP-2 activation using
various inhibitors of signaling molecules. Our results show that
K.-H. Kim et al. / FEBS Letters 581 (2007) 3303–3310 3309PD98059, an ERK pathway inhibitor, signiﬁcantly inhibits
pro-MMP-2 activation by ciglitazone, whereas genistein (a
tyrosine kinase inhibitor) and LY294002 (a phosphatidylinosi-
tol 3-kinase inhibitor) do not block the eﬀect of ciglitazone,
suggesting that the ERK pathway is involved in pro-MMP-2
activation. These results are consistent with a recent report
that the ERK pathway is involved in pro-MMP-2 activation
through an increase in MT1-MMP expression and that
PD98059 inhibits this process [9].
Recently, synthetic ligands for PPARc have been attracting
interest as therapeutic agents for cancer. Our results show that
diﬀerent PPARc agonists have diﬀerent potentials for aﬀecting
the invasiveness of some tumor cells through modulating pro-
MMP-2 activity. Some PPARc agonists may have negative ef-
fects on tumor angiogenesis and invasion. Therefore, further
explorations of the eﬀects of PPARc agonists on tumor metas-
tasis are necessary. In conclusion, our study demonstrates that
ciglitazone induces HT1080 tumor cell invasion through pro-
MMP-2 activation followed by ROS generation and ERK acti-
vation.
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